HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Marketing In Brief

This article was originally published in The Rose Sheet

Executive Summary

XanGo skin nutrition: First to market a premium mangosteen nutritional beverage with XanGo Juice, firm now is introducing Glimpse Intuitive Skin Care, which delivers mangosteen fruit's "potent" skin benefits via BioActive X³ Complex featuring "xanthone-rich ingredients that contain 30 times more antioxidant potency than green tea, according to Japanese in-vitro studies," company says Oct. 14. "Self-adjusting" formulation ensures that "the more someone uses it - men and women of all ages and ethnicities living in all climates - the more its nutrients target specific needs," XanGo claims, adding that it has signed the Compact for Safe Cosmetics and abstains from using chemicals that are potentially harmful to human health or the environment. Two Glimpse systems will roll out in November in the U.S. and Canada - one for normal-to-dry skin and one for normal-to-combination skin, each $200 and consisting of a cleanser, toner, serum and moisturizer; global rollout will continue in 2009, Lehi, Utah-based firm says. According to XanGo CEO Aaron Garrity, Glimpse mangosteen-based skin care will have same category-creating impact as XanGo Juice did when it launched in 2002; "the difference is that six years later we are in 23 countries with a sophisticated infrastructure and one million independent distributors to support the launch," he says

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015733

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel